HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) web only appendix All Versions of this Article: thx.2007.080903v1 63/1/27    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mastalerz, L Articles by Szczeklik, A Search for Related Content PubMed PubMed Citation Articles by Mastalerz, L Articles by Szczeklik, A

Prostaglandin E₂ systemic production in patients with asthma with and without aspirin hypersensitivity

A miel

¹ Department of Medicine, Jagiellonian University School of Medicine, Cracow, Poland
² Department of Applied Mathematics, University of Science and Technology, Cracow, Poland

Correspondence to:
Professor A Szczeklik, Jagiellonian University, School of Medicine, Department of Medicine, ul. Skawinska 8, 31–066 Krakow, Poland; mmszczek{at}cyf-kr.edu.pl

Background: A special regulatory role for prostaglandin E₂ has been postulated in aspirin-induced asthma. A study was undertaken to investigate the effects of aspirin on the systemic production of prostaglandin E₂ and cysteinyl leucotrienes in patients with asthma.

Methods: The urinary concentrations were determined of two main prostaglandin E₂ metabolites (13,14-dihydro-15keto-PGE₂ using a commercial enzyme immunoassay and 9,15-dioxo-11-hydroxy-2,3,4,5-tetranor-prostane-1,20-dioic acid by gas chromatography/mass spectrometry) and leucotriene E₄ using an immunoassay. Determinations were performed at baseline and following oral aspirin and celecoxib challenges in two well-defined asthma phenotypes: aspirin-sensitive and aspirin-tolerant patients.

Results: Aspirin precipitated bronchial reactions in all aspirin-sensitive patients but in none of the aspirin-tolerant patients. Celecoxib 400 mg was well tolerated by all patients except for one with aspirin-induced asthma. At baseline, the mean levels of prostaglandin E₂ metabolites did not differ between the groups. Following different aspirin provocation doses, the mean levels of the two main prostaglandin E₂ metabolites were decreased in the aspirin-tolerant group but remained unchanged in the aspirin-sensitive group. The dose of aspirin had no effect on the magnitude of the response on the prostaglandin E₂ metabolites and its duration. In both groups, urinary prostaglandin E₂ metabolites decreased following celecoxib challenge. No correlation was found between prostaglandin E₂ metabolites and leucotriene E₄.

Conclusions: Aspirin-precipitated asthmatic attacks are not associated with changes in the systemic production of prostaglandin E₂. In contrast, the systemic production of prostaglandin E₂ becomes depressed by aspirin in non-sensitive patients. This different response might indicate COX-1-dependent prostaglandin E₂ control of inflammatory cells in aspirin-induced asthma. Thus, PGE₂ is released during the clinical reactions to aspirin through an alternative COX-2 pathway. The clinical implications of this finding are in line with current observations of good tolerance of the selective COX-2 inhibitors in aspirin-sensitive patients.

This article has been cited by other articles:

				S. Farooque and T. H Lee Aspirin sensitivity and eicosanoids Thorax, January 1, 2008; 63(1): 2 - 4. [Full Text] [PDF]